Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs.

Boyer PL, Melody K, Smith SJ, Dunn LL, Kline C, Fischer DK, Dwivedi R, Clark P, Hughes SH, Ambrose Z.

J Virol. 2019 May 15;93(11). pii: e00224-19. doi: 10.1128/JVI.00224-19. Print 2019 Jun 1.

3.

Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.

Zhang Z, Walker M, Xu W, Shim JH, Girardet JL, Hamatake RK, Hong Z.

Antimicrob Agents Chemother. 2006 Aug;50(8):2772-81.

4.

Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.

Buckheit RW Jr, White EL, Fliakas-Boltz V, Russell J, Stup TL, Kinjerski TL, Osterling MC, Weigand A, Bader JP.

Antimicrob Agents Chemother. 1999 Aug;43(8):1827-34.

5.

Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.

Balzarini J.

Curr Top Med Chem. 2004;4(9):921-44. Review. Erratum in: Curr Top Med Chem. 2004;4(16):1825.

PMID:
15134549
6.

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.

Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PA, Arnold E.

J Mol Biol. 1994 Oct 28;243(3):369-87. Review.

PMID:
7525966
8.

Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.

Clevenbergh P, Cua E, Dam E, Durant J, Schmit JC, Boulme R, Cottalorda J, Beyou A, Schapiro JM, Clavel F, Dellamonica P.

HIV Clin Trials. 2002 Jan-Feb;3(1):36-44.

PMID:
11819184
9.

The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.

Auwerx J, Stevens M, Van Rompay AR, Bird LE, Ren J, De Clercq E, Oberg B, Stammers DK, Karlsson A, Balzarini J.

J Virol. 2004 Jul;78(14):7427-37.

10.

Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections.

Kuse N, Rahman MA, Murakoshi H, Tran GV, Chikata T, Koyanagi M, Nguyen KV, Gatanaga H, Oka S, Takiguchi M.

J Virol. 2015 Jul;89(14):7363-72. doi: 10.1128/JVI.00974-15. Epub 2015 May 13.

12.

Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.

Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ.

Antimicrob Agents Chemother. 2010 May;54(5):1973-80. doi: 10.1128/AAC.00870-09. Epub 2010 Mar 1.

13.

HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.

Menéndez-Arias L, Betancor G, Matamoros T.

Antiviral Res. 2011 Nov;92(2):139-49. doi: 10.1016/j.antiviral.2011.08.020. Epub 2011 Aug 28. Review.

PMID:
21896288
14.

Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.

Das K, Ding J, Hsiou Y, Clark AD Jr, Moereels H, Koymans L, Andries K, Pauwels R, Janssen PA, Boyer PL, Clark P, Smith RH Jr, Kroeger Smith MB, Michejda CJ, Hughes SH, Arnold E.

J Mol Biol. 1996 Dec 20;264(5):1085-100.

PMID:
9000632
15.

HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors.

Hachiya A, Marchand B, Kirby KA, Michailidis E, Tu X, Palczewski K, Ong YT, Li Z, Griffin DT, Schuckmann MM, Tanuma J, Oka S, Singh K, Kodama EN, Sarafianos SG.

J Biol Chem. 2012 Aug 24;287(35):29988-99. doi: 10.1074/jbc.M112.351551. Epub 2012 Jul 2.

16.

In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.

Sato A, Hammond J, Alexander TN, Graham JP, Binford S, Sugita K, Sugimoto H, Fujiwara T, Patick AK.

Antiviral Res. 2006 Jun;70(2):66-74. Epub 2006 Jan 25.

PMID:
16472877
17.

Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.

Smith SJ, Pauly GT, Akram A, Melody K, Ambrose Z, Schneider JP, Hughes SH.

J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):485-91. doi: 10.1097/QAI.0000000000001031.

18.

A mutation in the primer grip region of HIV-1 reverse transcriptase that confers reduced fidelity of DNA synthesis.

Gutiérrez-Rivas M, Menéndez-Arias L.

Nucleic Acids Res. 2001 Dec 15;29(24):4963-72.

19.

HIV-1 RT nonnucleoside inhibitors and their interaction with RT for antiviral drug development.

Zhou Z, Lin X, Madura JD.

Infect Disord Drug Targets. 2006 Dec;6(4):391-413. Review.

PMID:
17168804

Supplemental Content

Support Center